Are international guidelines for the prescription of adjuvant treatment for early breast cancer followed in clinical practice?
AIMS AND BACKGROUND: The results of several randomized trials and meta-analyses have been reported on adjuvant treatment for early breast cancer and treatment guidelines have been defined accordingly, but detailed data are lacking on the appropriateness of treatment prescription in clinical practice. METHODS: We performed a prospective, observational, multicenter study to monitor the prescription, delivery and effectiveness of radiotherapy following conservative surgery for early breast cancer; 1610 patients treated with postoperative radiation to the breast in 1997 were entered by 12 centers in Lombardy, Italy. Here we report the results of a secondary analysis focused on the prescription of medical adjuvant treatment (1547 eligible patients). RESULTS: Chemotherapy only was prescribed to 526 patients (33%), hormonal therapy only to 539 (33%), and both treatments to 85 patients (5%); 460 women (29%) received no medical adjuvant treatment. We compared the collected data with guidelines
Related Questions
- What is the difference between clinical criteria, practice guidelines, treatment protocols, clinical practice guidelines, and utilization management (UM) review criteria?
- Are international guidelines for the prescription of adjuvant treatment for early breast cancer followed in clinical practice?
- Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
